U.K. suspends Teva's hypothyroid generic; Lupin settles Glumetza patent fight;

@FiercePharma: Heinz might want pieces of the Pfizer nutrition business if they become available for antitrust reasons, FT reports. Story (reg. req.) | Follow @FiercePharma

> U.K. regulators suspended Teva Pharmaceutical Industries' ($TEVA) clearance for a version of the hypothyroidism drug levothyroxine on worries that the tablets might have dissolution problems affecting release of the active ingredient. News

> India's Lupin has won the right to launch its version of the diabetes drug Glumetza by 2016 in a patent settlement with Depomed and Santarus. Report

> Australian officials should revamp their pricing policies to take full advantage of low-cost generics, an economist advised. News

> A Washington state law requiring pharmacists to dispense emergency contraception despite their religious beliefs was struck down by a U.S. judge. Item

> Up to 60 R&D staff members will lose their jobs as Genzyme pulls out of Cambridge, England, and consolidates research into four global hubs. Story

> Questcor Pharmaceuticals reported a leap in quarterly profits on strong sales of its Acthar product, an injectable approved for multiple sclerosis exacerbations and nephrotic syndrome, among others. News

Biotech News

@FierceBiotech: Combined vaccine has low seizure risk in babies. News | Follow @FierceBiotech

@JohnCFierce: Simos Simeonidis at Cowen says he's surprised by the VVUS vote, but "we see FDA approval by April 17 as pretty much a done deal." | Follow @JohnCFierce

@RyanMFierce: $VVUS bulls being handsomely rewarded this morning. Stock up 110.5% at last glance in a.m. trading. Story | Follow @RyanMFierce

@FierceMedDev: Colonoscopy Can Lower Rate of Cancer Deaths by Half. Story via @BloombergNews (see Enzo story). News | Follow @FierceMedDev

> Satori snags $15M to fuel a trial on Alzheimer's drug. News

Vaccines News

> Vaccines mean that India celebrates its first year free of polio. Report

> World's first kala azar vaccine enters the clinic. Story

> Universal flu vaccine in first trial in the elderly, boosts responses. Item

> Nimenrix meningitis vaccine edges closer to the market for GSK. Article

> Prostate cancer vaccine teams up with antibody. Story

> Norovirus gets it in the nose. News

Manufacturing News

> Teva expected to pay big bucks for decision to use oversized vials. Report

> J&J Recall: Manufacturing issues believed behind CEO departure. Item

> Shire's $200 million Leed certified plant gets EMA nod. Story

> Pharmacists may seek arbitration to get recall costs from GSK. News

> Ranbaxy's manufacturing mess results in $606 million loss. Article

> FDA triples list of banned Chinese heparin ingredient makers. More

CRO News

> FDA cracks down on Chinese heparin material providers. News

> Ex-AstraZeneca researchers launch new CRO. Report

> ACRO blasts new rules that reveal docs' drug research payments. More

And Finally... Tuberculosis is staging a comeback in London, as some neighborhoods have infection rates similar to those in African countries in which the disease is endemic. Report